Video

VIDEO: Blinatumomab demonstrates ‘remarkable’ results for pediatric B-cell ALL

ORLANDO — In this video, Thomas Alexander, MD, pediatric oncologist and hematologist at the University of North Carolina, discusses a late breaking abstract presented at the ASH Annual Meeting and Exposition.

The trial revealed “remarkable” increases in disease free survival and overall survival, as well as decreases in toxicity, among pediatric patients with B-cell acute lymphoblastic leukemia who were treated with blinatumomab.

“Challenges remain in that it is relatively early in terms of follow-up and the medication blinatumomab is not easy to deliver, but most institutions have some familiarity with it, so it’s a reasonable new standard of care for pediatric B-cell ALL,” Alexander told HemOnc Today. – by Alaina Tedesco

Reference:

Brown PA, et al. LBA-1. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.

Disclosure: Alexander reports receiving travel expenses from AbbVie.

ORLANDO — In this video, Thomas Alexander, MD, pediatric oncologist and hematologist at the University of North Carolina, discusses a late breaking abstract presented at the ASH Annual Meeting and Exposition.

The trial revealed “remarkable” increases in disease free survival and overall survival, as well as decreases in toxicity, among pediatric patients with B-cell acute lymphoblastic leukemia who were treated with blinatumomab.

“Challenges remain in that it is relatively early in terms of follow-up and the medication blinatumomab is not easy to deliver, but most institutions have some familiarity with it, so it’s a reasonable new standard of care for pediatric B-cell ALL,” Alexander told HemOnc Today. – by Alaina Tedesco

Reference:

Brown PA, et al. LBA-1. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.

Disclosure: Alexander reports receiving travel expenses from AbbVie.

    See more from Discoveries from ASH: Leukemia